Citations 1
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
Tan, Carlyn Rose, Usmani, Saad Z., Derkach, Andriy , Corraes, Andre De Menezes Silva, Parrondo, Ricardo , Ailawadhi, S., Asoori, Sireesha, Dave, Mrugakshi, Popat, Rakesh, Morjaria, Oliver, Hajek, Roman , Htut, Myo , Kastritis, Efstathios, Dimopoulos, M A, Martínez-López, Joaquín, Nagarajan, Chandramouli, Bal, Susan, Costa, Luciano J., Einsele, Hermann, Steinbrunn, Torsten, Riedhammer, Christine , Banerjee, Rahul, Chng, Wee Joo, Tso, Allison CY, Lin, Yi, Martin, Tom, Mian, Hira, Martínez‐López, Joaquín , Mian, Hira , Tan, Carlyn R , de Meneze Silva Corraes, Andre, Mihalyova, Jana , Visram, Alissa , Kastritis, Efstathios , Martinez-Lopez, Joaquin , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J , Waldschmidt, Johannes M , Banerjee, Rahul , Tso, Allison , Martin, Thomas , Mian, Hira , Parrondo, Ricardo D , Derkach, Andriy , Usmani, Saad Z. , Corraes, Andre De Menezes Silva , Ailawadhi, Sikander , Popat, Rakesh , Hájek, Roman , Janakiram, Murali , Visram, Alissa , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J. , Steinbrunn, Torsten , Banerjee, Rahul , Chng, Wee Joo
Blood Advances | February 24, 2026 | Volume: 10 | Issue: 9 | Pages: 2937-2946
10.1182/bloodadvances.2025019231
Abstract Recent therapeutic advances, including bispecific antibodies (bsAbs), have improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM). However, early mortality (EM) remains a significant challenge, even in the era of novel immunotherapies. We conducted a multicenter, retrospective analysis of real-world patients with RRMM treated with commercial bsAbs to evaluate the incidence and causes of EM. Between May 2022 and June 2025, a total of 441 patients were treated across 7 countries. EM, defined as death within 12 months of therapy initiation, occurred in 148 patients (34%), with a median time from bsAb initiation to death of 2.87 months (interquartile range, 1.38-6.85). The leading cause of EM was progressive disease (72%), followed by infection (13%); regardless of the cause of death, 82% had active disease at the time of death. Our findings highlight that despite encouraging efficacy, EM remains high among real-world bsAb recipients, emphasizing the need for improved disease control strategies and supportive care interventions.